Back to search results

I-124 PET/CT Imaging for Thyroid Cancer

This observational study is looking at how a special imaging technique called I-124 PET/CT can help doctors understand and treat thyroid cancer. The study will use I-124 PET/CT imaging to see how much thyroid cancer remains after surgery, if the cancer has spread, and how it responds to treatments like radioactive iodine (RAI) therapy or other medications called kinase inhibitors. You might be able to join if you've had your thyroid removed for cancer, or if you have suspected or known recurrent or metastatic thyroid cancer. The goal is to see how useful this imaging is over five years to help doctors make better treatment decisions for patients like you.

Study design
This is an observational study planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years to observe the patterns and kinetics of RAI uptake.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06443866

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

Recruiting
Not specifiedAges 18+Observational
Miami Cancer Research Center, Inc.
~50 participants
Updated 2024-06-05 on ClinicalTrials.gov
What's tested:Disease status detectionTheranostic dosimetryI-124 PET/CT imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identification and characterization of RAI uptake pattern and kinetics
Measured over 5 years

Conditions

Thyroid Cancer
RAI-Refractory Thyroid Cancer

Explore related trials

Thyroid Gland Carcinoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Seza Gulec, MD · PRINCIPAL_INVESTIGATOR · CEO, MCRC

Who to contact

Seza Gulec, MD
[email protected]
786-693-0821
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Post-total thyroidectomy patients with diagnosis of thyroid cancer, any histology, subtype, any ATA risk category, for evaluation for residual disease, cervical or remote metastatic disease
Patients with known or suspected recurrent/metastatic thyroid cancer, identified by ultrasound (US), CT/MR/FDG-PET\|CT or elevated thyroglobulin (Tg).
Pretreatment and post-treatment evaluation of patients with thyroid cancer deemed RAI-indifferent/refractory who are considered for TKI
Age ≥ 18
Ability and willingness to give a written consent
Life expectancy \> 3 months
ECOG performance status ≤ 2

Exclusion

Cancers metastatic to thyroid
Age \< 18
Inability or unwillingness to give a written consent
Life expectancy \< 3 months
ECOG performance status ≥ 3
Pregnant and nursing women.

What this trial measures

  • Identification and characterization of RAI uptake pattern and kinetics5 years

    Measurements: 1. Administered activity 2. Cumulated activity 3. Standard uptake value Calculations: 1\. Radiation absorbed dose to the target Correlations to be reported: 1. Administered activity vs absorbed dose 2. Absorbed dose vs response 3. SUV at 48h vs response